SCHEMBL2122218

SCHEMBL2122218

N#Cc1c[nH]n2c(Nc3ccc4c(c3)OCO4)c(-c3ccc(OCc4ccccc4)cc3)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 1/20 0.44
▸ MAPT P10636 11/20 0.43
▸ GAA P10253 8/20 0.43
▸ MAPK1 P28482 3/20 0.43
▸ POLB P06746 2/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ TP53 P04637 2/20 0.42
▸ TSHR P16473 2/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ ADORA2B P29275 1/20 0.41
▸ ADORA1 P30542 1/20 0.41
▸ KDM5A P29375 2/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2123121 0.84 MAPT (0.54) MAPTGAAMAPK1POLBTP53
SCHEMBL2126473 0.83 MAPT (0.43) MAPTGAAMAPK1POLBALOX15
SCHEMBL2876451 0.81 MAPT (0.54) MAPTGAAMAPK1POLBALOX15
SCHEMBL2124362 0.81 MAPT (0.43) MAPTGAAMAPK1POLBALOX15
SCHEMBL2123492 0.79 KDM5A (0.46) MAPTPOLBTP53KDM5AKDM4E
SCHEMBL2875155 0.77 MAPT (0.52) MAPTGAAMAPK1POLBTP53
SCHEMBL2124513 0.75 LMNA (0.41) MAPTGAAMAPK1HSD17B10TP53
SCHEMBL2124185 0.69 KDM5A (0.50) MAPTPOLBTP53KDM5A
SCHEMBL2866440 0.69 KDM5A (0.54) MAPTTP53KDM5A
SCHEMBL2124751 0.68 MAPT (0.46) MAPTGAAPOLBTP53KDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
EP-2443123-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) Rigel Pharmaceuticals, Inc. (US) 2012-04-25 — — EP disclosed
WO-2010147898-A2 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS, INC. (US) 2010-12-23 — — WO disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK MAOB 1986/4885MAPT 4045/4885GAA 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback